Abstract 5129
Background
Describe adherence patterns to the medical control processes derived from belonging to a CG situation in a sample of patients in CG situation for hereditary breast and ovarian cancer (CMOH), and its consequences with Psychological Wellbeing.
Methods
Descriptive cross-sectional descriptive study. Participants: Women carriers of high penetrance genes for breast and ovarian cancer (BRCA1 / 2), during the months of July 2012 to May 2014 who continue to control the Hereditary Cancer program of the Català Oncología Institute. 176 women. For the adhesion assessment, 3 asdoca questions were asked, based on recommendations and guidelines, the scale of the psychological well-being (BP) of Ryff was used, validated in the Spanish population.
Results
Regarding breast autoexploration, 58.6% of the patients did not follow the correct follow-up (either by hypervigilance or hypovigilance). Regarding the follow-ups in mammographic controls, 51.4% of the patients do the correct follow-up. When analyzing the relationship between breast self-exploration and the dimensions of psychological well-being, no statistically significant differences were found in any case, the same happens with mammographic controls Regarding the follow-up by MRI, 51.4% of the patients follow the correct one. A relationship is found in the dimension of Autonomy and Purpose in life.
Conclusions
The literature reports that there are well-defined and structured medical treatment protocols that allow monitoring of the carrier patients and that these are understandable to them with the final objective that patients have strategies to manage the situation without uncertainty (Ringwald et al., 2016). One possible explanation is that patients do not fully understand the protocols or that there are other personality variables that are modulating this aspect, such as a passive coping style or a high perception of risk (Den Heijer et al., 2013; Gopie et al., 2012). Conclusions Our population, approximately 50% of patients do not adhere to the proposed follow-up measures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Melinda Gonzalez Concepcion.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1908 - Androgen Receptor (AR) Aberrations in Patients (Pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated With Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) in TITAN
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4058 - 68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic castration resistant prostate cancer patients
Presenter: Anouk de Jong
Session: Poster Display session 3
Resources:
Abstract
2226 - Spatial-Temporal Change in Quantitative Total Bone Imaging (QTBI) and Circulating Tumor Cells (CTCs) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide (ENZA)
Presenter: Glenn Liu
Session: Poster Display session 3
Resources:
Abstract
5795 - Efficacy of Enzalutamide in Hormone-sensitive Metastatic Prostate Cancer: Clinical Utility of 18F-Choline PET and Whole Body MRI.
Presenter: Susanne Osanto
Session: Poster Display session 3
Resources:
Abstract
899 - Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result
Presenter: Jungreem Woo
Session: Poster Display session 3
Resources:
Abstract
3094 - Circulating tumor cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
2527 - Circulating Tumor Cells (CTC) count and Prostate-Specific Antigen (PSA) response measures in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients (pts) treated with Docetaxel (Doc)
Presenter: Rebeca Lozano Mejorada
Session: Poster Display session 3
Resources:
Abstract
6106 - Assessing the clinical relevance of drug–drug interactions (DDI) with darolutamide (DARO)
Presenter: Christian Zurth
Session: Poster Display session 3
Resources:
Abstract
2237 - KEYNOTE-921: phase 3 study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
2241 - KEYNOTE-641: Phase 3 Study of Pembrolizumab (pembro) Plus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: Julie Graff
Session: Poster Display session 3
Resources:
Abstract